Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas
Study Status
Open to Enrollment
Study Description
Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat may kill more cancer cells.
The purpose of this phase 2 trial is to study how well giving bortezomib together with vorinostat works in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
Patients will receive Vorinostat 400 mg (total daily dose as a single dose) on days 1-5 and days 8-12. Patients will receive Bortezomib 1.3 mg/m2/d IV on days 1, 4, 8, and 11. The regimen is repeated every 3 weeks.
Patients who experience a complete or partial response after at least one year of treatment may go off treatment while remaining on the study, and then resume study treatment upon disease progression if the study remains open.
Click here to visit our lymphoma blog.
Disease Status and/or Stage
Relapsed or Refractory Mantle Cell or Diffuse Large B-Cell Lymphoma
Sponsor
National Cancer Institute
Key Eligibility
- Men and women age 18 and older
- Diagnosed with 1 of the following:
- Mantle Cell Lymphoma
- Previously treated or untreated
- Previously treated or untreated
- Diffuse Large B-Cell Lymphoma
- Have had at least 1 prior systemic therapy
- No prior treatment with bortezomib
- Have had at least 1 prior systemic therapy
- Mantle Cell Lymphoma
- More detailed eligibility discussed when you contact the study team
Principal Investigator
Contact
- June Greenberg, RN
- (212) 746-2651
- jdg2002@med.cornell.edu
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (212) 746-9498
roh2026@med.cornell.edu
